Press Releases
Press Releases
-
March 7, 2019
Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies -
March 6, 2019
Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women -
March 6, 2019
Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance -
March 6, 2019
Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection -
March 5, 2019
Gilead Announces Senior Management Change -
March 5, 2019
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12 -
February 26, 2019
Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV -
February 11, 2019
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH) -
February 4, 2019
Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend -
February 4, 2019
Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results